Research programme: anti-cancer therapeutics - Proteros biostructures/Janssen

Drug Profile

Research programme: anti-cancer therapeutics - Proteros biostructures/Janssen

Alternative Names: Covalent Flt3-Cys828 inhibitors - Proteros biostructures; Fms like tyrosine kinase 3 inhibitors - Proteros biostructures

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Proteros Biostructures
  • Developer Janssen; Proteros Biostructures
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Research Cancer

Most Recent Events

  • 27 Jul 2017 Proteros biostructures and Janssen Biotech enter into a research collaboration for developing cancer therapeutics against epigenetic targets
  • 03 Jun 2016 Preclinical trials in Acute myeloid leukaemia (Flt3 mutant) in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top